Skip to content Skip to footer
Cytonics Corporation
Cytonics Corporation
Cytonics Corporation
Close

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

January 6, 2026596Views
You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

Read More

#62 🙏 Another Year Full of Gratitude

December 26, 2025511Views
As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions.

Read More

#62 🙏 Another Year Full of Gratitude

December 26, 2025393Views
As the year winds down, I’ve found myself thinking less about milestones and more about people. The ones doing the work day in and day out. The ones asking good questions. The ones choosing to support something that takes patience, care, and long-term thinking. I’m deeply thankful to our investors for the trust you…

Read More

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

December 20, 2025541Views
Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain.

Read More

#60 👎 Where Big Pharma Tried And Failed

November 4, 2025633Views
Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

Read More

#60 👎 Where Big Pharma Tried And Failed

November 4, 2025688Views
Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

Read More

#59 🧬 Why is A2M being called a physiological guardian?

October 21, 2025647Views
Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…

Read More

#57: 👎 Why Cytonics Turned Down VC

August 27, 2025625Views
Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.

Read More

#55 🧬 Perfecting Nature’s Blueprint

July 1, 2025390Views
Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.

Read More

Marketing by Katapult Marketing
© 2026 Cytonics Corporation – All rights reserved

Get fresh updates
Subscribe

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 30 East 23rd Street, 2nd Floor, NY, NY 10010, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA’s BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor’s documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Receive News

Download Exclusive Investor Presentation & Stay Updated

Name(Required)
Privacy(Required)